CURIS INC Annual Report - How They Did This Year

I’ve put together a guide to help you understand how Curis Inc. performed this year. Think of this as a plain-English breakdown of their latest annual report to help you decide if this company fits your investment goals.

1. What does this company do?

Curis is a biotech company focused on discovering and developing cancer treatments. They do not have products on the market yet, so they aren't making steady sales. Their main project is emavusertib, a drug currently in clinical trials for blood cancers like AML and MDS. They also earn royalties from Erivedge, a skin cancer drug sold by Genentech/Roche.

2. Financial performance

Curis is currently operating at a loss, which is common for a biotech company in the development stage. In 2025, they reported a loss of $58.4 million, compared to $62.1 million in 2024. Their primary income source is Erivedge royalties, which generated approximately $7.2 million. As of March 2026, there were 39.98 million shares outstanding.

3. Major wins and challenges

The company’s primary challenge is managing limited cash reserves. Because they do not have a commercial product generating significant revenue, they rely on selling new shares to fund their research and development. In 2025, they raised $15 million through this method. While this provides necessary operating capital, it results in "dilution," where the issuance of new shares reduces the ownership percentage and potential value of existing shares. The company's future success is tied directly to the progress of emavusertib through clinical trials.

4. Financial health

At the end of 2025, the company held approximately $28.5 million in cash. With monthly operating expenses ranging between $4.5 million and $5 million, current projections suggest their cash runway extends into the second half of 2026. Management has noted that additional capital will be required to continue operations beyond that timeframe.

5. Key risks that could impact the stock

• Dilution: Reliance on equity financing means your ownership stake may shrink. If the stock price remains low, the company must issue a higher volume of shares to raise the same amount of capital.
• Clinical Success: The stock price is highly sensitive to the results of drug trials. Any negative data regarding safety or effectiveness could significantly impact the company's valuation.
• Cash Burn: If trial costs exceed expectations or if the company cannot secure a development partner, their financial position could deteriorate rapidly.
• Regulatory Hurdles: Evolving FDA requirements for testing can increase costs and potentially delay the path to drug approval.
• Royalty Concentration: Revenue from Erivedge is subject to market competition, which could reduce the company's only steady stream of income.

6. Future outlook

In 2026, the company intends to complete key stages of their clinical trials. They are actively seeking partners to help offset development costs, though these arrangements are not guaranteed. Investors should anticipate volatility as the company approaches significant trial milestones. The central question for the coming year is whether the company can secure the necessary funding to reach their next major development goal.

Disclaimer: I am an AI, not a financial advisor. Biotech stocks are high-risk. Please do your own research before investing.